702 related articles for article (PubMed ID: 19262495)
1. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
[TBL] [Abstract][Full Text] [Related]
2. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
Hypertens Res; 2011 Feb; 34(2):268-73. PubMed ID: 21124330
[TBL] [Abstract][Full Text] [Related]
3. Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.
Abe M; Okada K; Maruyama N; Matsumoto S; Maruyama T; Fujita T; Matsumoto K; Soma M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1027-37. PubMed ID: 20649501
[TBL] [Abstract][Full Text] [Related]
4. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
Ohishi M; Takagi T; Ito N; Terai M; Tatara Y; Hayashi N; Shiota A; Katsuya T; Rakugi H; Ogihara T
Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
[TBL] [Abstract][Full Text] [Related]
5. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
Saito F; Fujita H; Takahashi A; Ichiyama I; Harasawa S; Oiwa K; Takahashi N; Otsuka Y; Uchiyama T; Kanmatsuse K; Kushiro T
Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
[TBL] [Abstract][Full Text] [Related]
6. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease.
Tomino Y; Shimizu Y; Hamada C; Kurusu A; Ohsawa I; Suzuki Y; Tsuge T; Io H; Kobayashi N; Takeda Y; Asanuma K; Tanaka Y; Suzuki H; Nakata J; Takara K; Horikoshi S
J Nephrol; 2011; 24(6):756-63. PubMed ID: 21360472
[TBL] [Abstract][Full Text] [Related]
7. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
[TBL] [Abstract][Full Text] [Related]
8. Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
Yamada H; Suga N; Maeda K; Kimura Y; Miura N; Futenma A; Imai H
Arzneimittelforschung; 2010; 60(2):64-70. PubMed ID: 20329653
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
Miyagawa K; Dohi Y; Nakazawa A; Sugiura T; Yamashita S; Sato K; Kimura G
Clin Exp Hypertens; 2010 Jan; 32(1):1-7. PubMed ID: 20144066
[TBL] [Abstract][Full Text] [Related]
10. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
11. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
12. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
Miwa Y; Tsuchihashi T; Ohta Y; Tominaga M; Kawano Y; Sasaguri T; Ueno M; Matsuoka H
Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
[TBL] [Abstract][Full Text] [Related]
13. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
[TBL] [Abstract][Full Text] [Related]
14. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
Abe M; Okada K; Maruyama T; Matsumoto K
Pharmacotherapy; 2009 Sep; 29(9):1061-72. PubMed ID: 19698011
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the renoprotective effects of benidipine and valsartan in primary hypertensive patients with proteinuria.
Peng T; Hu Z; Xia Q; Jiang B; Li X; Yang X
Arzneimittelforschung; 2009; 59(12):647-50. PubMed ID: 20108651
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
17. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.
Fujita T; Ando K; Nishimura H; Ideura T; Yasuda G; Isshiki M; Takahashi K;
Kidney Int; 2007 Dec; 72(12):1543-9. PubMed ID: 17943080
[TBL] [Abstract][Full Text] [Related]
18. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study.
Martinez-Martin FJ; Saiz-Satjes M
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1347-55. PubMed ID: 19018688
[TBL] [Abstract][Full Text] [Related]
19. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis.
Ishimitsu T; Kameda T; Akashiba A; Takahashi T; Ohta S; Yoshii M; Minami J; Ono H; Numabe A; Matsuoka H
Hypertens Res; 2007 Jul; 30(7):621-6. PubMed ID: 17785930
[TBL] [Abstract][Full Text] [Related]
20. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
